IVZ media thread, page-56

First 56 Last

Share
Profile

Follow
GordonAcko

1,005 Posts.

113

11/07/20

10:30

Post #: 45795007
Share

Originally posted by Chrimata: ↑

The article is fine but management need to put more into marketing this company. The money saved in the last few months needs to be put to use.

The O&G market has been depressed the last few months so marketing money has been saved. Stock head articles are retweeted by the same people continually (including myself) to the same networks and the Kalkine articles don’t generate traffic.

If I can give the company some suggestions...

- The website to be updated (I thought this was happening back in February)
- A company presentation (haven’t had one for 8 months)
- Video interviews (not hotcoppers)
- Talk to media outlets (as many as possible)
- Co-promote through online outlets not previously used (plenty of services exist)

Investors (new and old) need to know the below:

- How many realise we have the largest undrilled O&G target on the ASX?
- How many realise this is an onshore well that has multiple stacked targets?
- How many realise the cost difference for an onshore well compared to offshore?
- How many realise we have Mobil’s data set worth $30mil USD?
- How many know of the power shortage in Southern Africa?
- How many know of the coal fired power stations being turned off?
- How many know of the updates in the region?
- How many know the nearby gas fields are running low in the coming years?
- How many realise management met with the Zimbabwean president?
- How many realise we have backing of the government to get this target drilled?

The current articles have served their purpose, but we don’t need another stock head article with children holding money, or people popping a champagne bottle as the graphic...... This is a serious target and needs serious backing going forward.

The company cannot be frugal in the coming months in terms of marketing/telling the story. Nothing substantial for quite some time now, things clearly need to change going forward. This especially rings true with the news we are all expecting...

Expand

Inflation in Zimbabwe rose to 10.6 percent in 2018, and is projected to jump dramatically to 319.04 percent in thanks for your thoughtful post
everything you have said is valid
swimming upstream against the tide
i think that the whole dynamic of who is steering the ship is in question
the influence of the Zimbabwe government should not be underestimated

Inflation and currency is out of control. A lot can go wrong.

the off take has been imminent for it seems forever.

A bit more certainy is needed.

IVZ Price at posting: 2.8¢ Sentiment: Sell Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 7,602 more messages in this thread...

First 56 Last

Add IVZ (ASX) to my watchlist

(20min delay)
Last 7.7¢		Change 0.000(0.00%)		Mkt cap ! $116.7M

Open	High	Low	Value	Volume
7.5¢	7.7¢	7.4¢	$74.12K	990.8K

Buyers (Bids)

No.	Vol.	Price($)
2	56930	7.4¢

Sellers (Offers)

Price($)	Vol.	No.
7.7¢	12986	1

View Market Depth

No.	Vol.	Price($)
2	56930	0.074
2	39931	0.073
3	84432	0.072
3	89050	0.071
5	396817	0.070

Price($)	Vol.	No.
0.077	12986	1
0.078	254968	4
0.080	153368	5
0.081	1000	1
0.082	72100	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

IVZ (ASX) Chart

IVZ media thread, page-56

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IVZ media thread, page-56

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News